Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 536

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease

Open access
Kim, So Ra, Lee, Sang-Guk, Kim, Soo Hyun, Kim, Jin Hee, Choi, Eunhye, Cho, Wonhee, Rim, John Hoon, Hwang, Inhwa, Lee, Chan Joo, Lee, Minyoung, Oh, Chang-Myung, Jeon, Justin Y., Gee, Heon Yung, Kim, Jeong-Ho, Lee, Byung-Wan, Kang, Eun Seok, Cha, Bong-Soo, Lee, Myung-Shik, Yu, Je-Wook, Cho, Jin Won, Kim, Jung-Sun, Lee, Yong-ho·2020·Nature Communications

Abstract

Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events in humans with type 2 diabetes (T2D); however, the underlying mechanism remains unclear. Activation of the NLR family, pyrin domain-containing 3 (NLRP3) inflammasome and subsequent interleukin (IL)-1β release induces atherosclerosis and heart failure. Here we show the effect of SGLT2 inhibitor empagliflozin on NLRP3 inflammasome activity. Patients with T2D and high cardiovascular risk receive SGLT2 inhibitor or sulfonylurea for 30 days, with NLRP3 inflammasome activation analyzed in macrophages. While the SGLT2 inhibitor’s glucose-lowering capacity is similar to sulfonylurea, it shows a greater reduction in IL-1β secretion compared to sulfonylurea accompanied by increased serum β-hydroxybutyrate (BHB) and decreased serum insulin. Ex vivo experiments with macrophages verify the inhibitory effects of high BHB and low insulin levels on NLRP3 inflammasome activation. In conclusion, SGLT2 inhibitor attenuates NLRP3 inflammasome activation, which might help to explain its cardioprotective effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-15983-6

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 536

Metadata

Authors
Kim, S. R., Lee, S.-G., Kim, S. H., Kim, J. H., Choi, E., Cho, W., Rim, J. H., Hwang, I., Lee, C. J., Lee, M., Oh, C.-M., Jeon, J. Y., Gee, H. Y., Kim, J.-H., Lee, B.-W., Kang, E. S., Cha, B.-S., Lee, M.-S., Yu, J.-W., Cho, J. W., Kim, J.-S., & Lee, Y.-H.
Venue
Nature Communications
Published
2020-05-01
Volume
11
Issue
1
Pages
2127-2127
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3023354007
Cited by
536
References
42
FWCI
17.70
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • National Research Foundation of Korea (NRF-2017R1C1B5015044, NRF-2016R1A5A1010764)
  • Ministry of Trade, Industry and Energy (10063335)
  • Yonsei University | Yonsei University College of Medicine (6-2016-0082)
  • Korea Health Industry Development Institute (HI17C0913)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. https://app.cochat.ai/papers/10.1038/s41467-020-15983-6
The paper
Kim, S. R., Lee, S.-G., Kim, S. H., Kim, J. H., Choi, E., Cho, W., Rim, J. H., Hwang, I., Lee, C. J., Lee, M., Oh, C.-M., Jeon, J. Y., Gee, H. Y., Kim, J.-H., Lee, B.-W., Kang, E. S., Cha, B.-S., Lee, M.-S., Yu, J.-W., . . . Lee, Y.-H. (2020). SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nature Communications. https://doi.org/10.1038/s41467-020-15983-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.